Investigators from 16 prospective epidemiologic cohorts, part of the NCI Cohort Consortium, and a select number of case control studies established a cohort-based genome-wide association study (GWAS) of glioma ("GliomaScan"). GliomaScan is funded by the National Cancer Institute (NCI), and involves a genome-wide scan of common genetic variants to identify markers of susceptibility to glioma. Genotyping was conducted by the NCI Cancer Genomics Research (CGR) Laboratory.
DCEG investigators conducted a new, independent GWAS of glioma using 1,856 cases and 4,955 controls from 14 studies belonging to the NCI Cohort Consortium, three case-control studies, and one population-based case-only study. Cases were newly diagnosed glioma [ICDO-3 codes 9380-9480 or equivalent], and controls were cancer-free. Newly genotyped controls (n=2,429) were selected in a 2:1 ratio, frequency matched on age, sex and race/ethnicity. GWAS data were already available on 2,591 controls and 12 cases from cohorts that had participated in the PANSCAN, CGEMS, and the NCI lung cancer GWAS.